Bliss GVS Pharma Limited (BLISSGVS.BO)
INR 120.15
(3.0%)
INR 120.15
(3.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.47 Billion INR | 16.12% |
| 2022 | 1.35 Billion INR | -21.36% |
| 2021 | 762.36 Million INR | 27.89% |
| 2020 | 1.26 Billion INR | -21.38% |
| 2019 | 1.49 Billion INR | -20.35% |
| 2018 | 1.95 Billion INR | 62.15% |
| 2017 | 816.66 Million INR | 1.27% |
| 2016 | 1.11 Billion INR | -30.01% |
| 2015 | 1.79 Billion INR | 36.4% |
| 2014 | 1.23 Billion INR | 33.21% |
| 2013 | 986.01 Million INR | -10.75% |
| 2012 | 1.1 Billion INR | 56.87% |
| 2011 | 704.3 Million INR | 347.88% |
| 2010 | -284.13 Million INR | -153.41% |
| 2009 | 536.91 Million INR | 15.39% |
| 2008 | 461.06 Million INR | 16.6% |
| 2007 | 395.41 Million INR | 318.57% |
| 2006 | 94.47 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 343.3 Million INR | 709.36% |
| 2024 Q2 | 465.14 Million INR | 20.96% |
| 2023 Q2 | 669.7 Million INR | 128.36% |
| 2023 Q1 | 293.26 Million INR | 1297.36% |
| 2023 Q4 | 283.47 Million INR | -42.28% |
| 2023 Q3 | 491.16 Million INR | -26.66% |
| 2023 FY | - INR | 16.12% |
| 2022 Q2 | 266.96 Million INR | -41.79% |
| 2022 Q4 | 20.98 Million INR | -96.06% |
| 2022 Q3 | 533.32 Million INR | 99.78% |
| 2022 Q1 | 458.62 Million INR | -3.22% |
| 2022 FY | - INR | -21.36% |
| 2021 FY | - INR | 27.89% |
| 2021 Q2 | 348.58 Million INR | -17.82% |
| 2021 Q1 | 424.18 Million INR | 80.04% |
| 2021 Q4 | 473.89 Million INR | 17.88% |
| 2021 Q3 | 402.01 Million INR | 15.33% |
| 2020 Q3 | 423.94 Million INR | 59.17% |
| 2020 Q2 | 266.34 Million INR | 0.43% |
| 2020 Q4 | 235.6 Million INR | -44.42% |
| 2020 Q1 | 265.18 Million INR | -22.16% |
| 2020 FY | - INR | -21.38% |
| 2019 Q1 | 510.73 Million INR | 12.53% |
| 2019 Q2 | 383.62 Million INR | -24.89% |
| 2019 Q3 | 384.62 Million INR | 0.26% |
| 2019 Q4 | 340.69 Million INR | -11.42% |
| 2019 FY | - INR | -20.35% |
| 2018 Q2 | 664.02 Million INR | 91.21% |
| 2018 Q1 | 347.27 Million INR | -19.38% |
| 2018 FY | - INR | 62.15% |
| 2018 Q4 | 453.86 Million INR | 14.5% |
| 2018 Q3 | 396.37 Million INR | -40.31% |
| 2017 Q1 | 675.85 Million INR | -2.42% |
| 2017 FY | - INR | 1.27% |
| 2017 Q4 | 430.76 Million INR | -14.52% |
| 2017 Q3 | 503.95 Million INR | -19.52% |
| 2017 Q2 | 626.18 Million INR | -7.35% |
| 2016 Q4 | 692.6 Million INR | 31.28% |
| 2016 Q3 | 527.58 Million INR | 17.67% |
| 2016 Q2 | 448.35 Million INR | -7.33% |
| 2016 Q1 | 483.82 Million INR | -7.22% |
| 2016 FY | - INR | -30.01% |
| 2015 Q3 | 352.1 Million INR | -31.36% |
| 2015 Q1 | 414.12 Million INR | 0.0% |
| 2015 Q4 | 521.47 Million INR | 48.1% |
| 2015 FY | - INR | 36.4% |
| 2015 Q2 | 512.99 Million INR | 23.88% |
| 2014 FY | - INR | 33.21% |
| 2013 FY | - INR | -10.75% |
| 2012 Q2 | 377.38 Million INR | 46.23% |
| 2012 Q4 | 203.64 Million INR | -25.85% |
| 2012 FY | - INR | 56.87% |
| 2012 Q1 | 258.08 Million INR | 0.0% |
| 2012 Q3 | 274.62 Million INR | -27.23% |
| 2011 FY | - INR | 347.88% |
| 2010 FY | - INR | -153.41% |
| 2009 FY | - INR | 15.39% |
| 2008 FY | - INR | 16.6% |
| 2007 FY | - INR | 318.57% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 84.62% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.606% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 78.449% |
| Granules India Limited | 8.6 Billion INR | 82.81% |
| Indoco Remedies Limited | 2.64 Billion INR | 44.125% |
| Achyut Healthcare Limited | 524 Thousand INR | -282157.634% |
| Ajanta Pharma Limited | 12.56 Billion INR | 88.229% |
| Alkem Laboratories Limited | 24.19 Billion INR | 93.887% |
| Alpa Laboratories Limited | 86.12 Million INR | -1617.266% |
| Brooks Laboratories Limited | 41.72 Million INR | -3444.455% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 37.244% |
| Bajaj HealthCare Limited | 444.51 Million INR | -232.728% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.325% |
| Eris Lifesciences Limited | 6.98 Billion INR | 78.83% |
| FDC Limited | 4.4 Billion INR | 66.399% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 86.962% |
| Gufic Biosciences Limited | 1.48 Billion INR | 0.098% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 78.445% |
| Ipca Laboratories Limited | 13.29 Billion INR | 88.879% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -357.253% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1887.844% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2372.634% |
| Laurus Labs Limited | 8 Billion INR | 81.526% |
| Lupin Limited | 36.96 Billion INR | 95.999% |
| Mankind Pharma Limited | 28.09 Billion INR | 94.736% |
| Medicamen Biotech Limited | 245.66 Million INR | -502.064% |
| Medico Remedies Limited | 150.37 Million INR | -883.541% |
| Megasoft Limited | 284.73 Million INR | -419.448% |
| NATCO Pharma Limited | 18.79 Billion INR | 92.131% |
| Piramal Pharma Limited | 13.05 Billion INR | 88.671% |
| RPG Life Sciences Limited | 1.28 Billion INR | -15.414% |
| Sigachi Industries Limited | 883.39 Million INR | -67.425% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.931% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 68.378% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -243.74% |
| Unichem Laboratories Limited | 742.35 Million INR | -99.235% |
| Wanbury Limited | 985.49 Million INR | -50.081% |
| Windlas Biotech Limited | 781.72 Million INR | -89.202% |
| ZIM Laboratories Limited | 462.09 Million INR | -220.069% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.369% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 139.639% |
| Divi's Laboratories Limited | 25.43 Billion INR | 94.184% |
| Hester Biosciences Limited | 539.47 Million INR | -174.164% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 50.935% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -116.696% |
| Bal Pharma Limited | 345.59 Million INR | -327.97% |
| Strides Pharma Science Limited | 3.76 Billion INR | 60.713% |
| Venus Remedies Limited | 711.8 Million INR | -107.787% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 62.168% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 5.42% |
| Shilpa Medicare Limited | 2.58 Billion INR | 42.85% |
| Aarti Drugs Limited | 3.24 Billion INR | 54.472% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 43.258% |
| Suven Life Sciences Limited | -992.78 Million INR | 248.979% |
| Ind-Swift Limited | 1.06 Billion INR | -38.867% |
| Valiant Laboratories Limited | 12.73 Million INR | -11510.252% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 84.156% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 152.413% |
| Themis Medicare Limited | 562.6 Million INR | -162.889% |
| Hikal Limited | 2.69 Billion INR | 45.063% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 95.775% |
| Sequent Scientific Limited | 549.8 Million INR | -169.012% |
| Novartis India Limited | 1.26 Billion INR | -16.523% |
| Wockhardt Limited | 1.08 Billion INR | -36.947% |
| Jubilant Pharmova Limited | 8 Billion INR | 81.526% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -11223.151% |
| Neuland Laboratories Limited | 4.74 Billion INR | 68.851% |
| Morepen Laboratories Limited | 1.72 Billion INR | 14.307% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -414.579% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -745.421% |